
    
      -  Primary objective: Descriptive analysis of the proportion (%) of adverse events (AEs),
           serious adverse events (SAEs), unexpected adverse eventsâˆ™adverse drug reactions and AEs
           of special interest (AESI) in patients who are treated with Xigduo XR for type 2
           diabetes mellitus by physicians in the normal clinical practice setting over a period of
           12 or 24 weeks.

        -  Secondary objective: To follow the changes of values of hemoglobin A1c (HbA1c), fasting
           plasma glucose (FPG), 2-hr post-prandial glucose (PPG-2hr), blood pressure, abdominal
           circumference and body weight and self-reported data in this cohort of patients from
           baseline to completion of the study.

      To evaluate the safety and tolerability of Xigduo XR in patients with type 2 diabetes
      mellitus based on conducted laboratory test (Laboratory tests are not mandatory because of
      the non-interventional nature of this study)
    
  